Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6368-6375

  Rege, Kaushal ^a   Patel, Suraj J ^a   Megeed, Zaki ^a   Yarmush, Martin L ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CYSTEINYLGLUTAMINYLLYSYLHISTIDYLHISTIDYLASPARAGINYLTYROSYL LEUCYLCYSTEINYLGLYCYLGLYCYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDINE; CYSTEINYLGLUTAMINYLLYSYLHISTIDYLHISTIDYLASPARAGINYLTYROSYL LEUCYLCYSTEINYLGLYCYLGLYCYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSYLLYSYL LEUCYLALANYLLYSYLLEUCYLALANYLLYSYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDINE; HISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLLYSYLLEUCYLALANYLLYSYL LEUCYLALANYLLYSYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSYLCYSTEINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY MLN591; MONOCLONAL ANTIBODY MLN591 HISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYL LYSYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSYLCYSTEINE CONJUGATE; PEPTIDE ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOCONJUGATES; MALE; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROSTATIC NEOPLASMS;

EID: 34447136161     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3658     Document Type: Article

References (50)

1. Gulley J, Dahut WL. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology 2003;62 Suppl 1:147-54.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
3. Zietman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer 1993;71:959-69.
4. Rumohr JA, Chang SS. Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr Opin Investig Drugs 2006;7:529-33.
5. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
6. Israeli RS, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
7. Silver DA, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
8. Sweat SD, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
9. Chang SS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
10. Su SL, et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-3.
11. Weissensteiner T. Prostate cancer cells show a nearly 100-fold increase in the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM). Nucleic Acids Res 1998;26:687.
12. Liu H, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-60.
13. Rajasekaran SA, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003;14:4835-45.
14. Fracasso G, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53:9-23.
15. Schulke N, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 2003;100:12590-5.
16. Bander NH, et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
17. Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol 2003;21:556-62.
18. Pierson TC, Doms RW. HIV-1 entry inhibitors: new targets, novel therapies. Immunol Lett 2003;85:113-8.
19. Nakanishi M, et al. Basic peptides as functional components of non-viral gene transfer vehicles. Curr Protein Pept Sci 2003;4:141-50.
20. Fuessel S, et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006;66:811-21.
21. Chromek M, et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006;12:636-41.
22. Berezin V, Bock E. NCAM mimetic peptides: Pharmacological and therapeutic potential. J Mol Neurosci 2004;22:33-9.
23. Ellerby HM, et al. Anti-cancer activity of targeted proapoptotic peptides. Nat Med 1999;5:1032-8.
24. Tamm I, et al. Peptides targeting caspase inhibitors. J Biol Chem 2003;278:14401-5.
25. Mai JC, et al. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001;61:7709-12.
26. Walensky LD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70.
27. Warren P, et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Cancer Res 2001;61:6783-7.
28. Arap W, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 2002;99:1527-31.
29. Javadpour MM, et al. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996;39:3107-13.
30. Trapp S, Horobin RW. A predictive model for the selective accumulation of chemicals in tumor cells. Eur Biophys J 2005;34:959-66.
31. Costantini P, et al. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000;92:1042-53.
32. Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol Cancer Ther 2004;3:597-603.
33. Friedman M. Applications of the ninhydrin reaction for analysis of amino acids, peptides, and proteins to agricultural and biomedical sciences. J Agric Food Chem 2004;52:385-406.
34. Smiley ST, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 1991;88:3671-5.
35. Troyer JK, Beckett ML, Wright, GL, Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232-42.
36. Leung S, et al. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001;91:846-50.
37. DeMarzo AM, et al. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
38. Mackey TJ, et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998;52:1085-90.
39. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961;191:144-8.
40. Lupold SE, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002;62:4029-33.
41. Chu TC, et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006;66:5989-92.
42. Farokhzad OC, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-72.
43. Smith-Jones PM, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237-43.
44. Ross JS, et al. Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev 2005;24:521-37.
45. Marks AJ, et al. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res 2005;65:2373-7.
46. Kelly KA, Jones DA. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia 2003;5:437-44.
47. Papo N, et al. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 2006;66:5371-8.
48. Papo N, Shai Y. New lytic peptides based on the DL-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003;42:9346-54.
49. Papo N, et al. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003;278:21018-23.
50. Hamann PR, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002;13:40-6.